← Back to Search

Smoking Cessation Interventions for Lung Cancer Screening Patients

N/A

Waitlist Available

Led By Scott D Halpern, MD PhD

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has a low-dose computed tomography (LDCT) scan ordered by their physician

Aged 18 years or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks, 3 months, 6 months,12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effectiveness of four interventions to help smokers quit smoking for at least six months.

Who is the study for?

This trial is for underserved adult smokers referred for lung cancer screening. Participants must be 18+, have a cell phone with text or internet, and meet at least one of these: Black, Hispanic, rural resident, or low income. They should smoke at least 1 cigarette per day and not use e-cigarettes.

What is being tested?

The study compares four ways to help people quit smoking: removing cost barriers to quitting aids, offering money rewards for staying smoke-free, using a mobile app designed to support quitting efforts. The goal is to see which method helps maintain no smoking for six months.

What are the potential side effects?

There may not be direct medical side effects from the interventions since they involve financial incentives and digital tools rather than medications. However, participants might experience stress or frustration related to trying to quit smoking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My doctor has ordered a low-dose CT scan for me.

Select...

I am 18 years old or older.

Select...

I smoke at least one cigarette a day.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks, 3 months, 6 months,12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks, 3 months, 6 months,12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks, 3 months, 6 months,12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Biochemically confirmed smoking abstinence sustained for 6 months

Secondary study objectives

Health-related quality of life

Motivation to quit

Perceived barriers to cessation

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Active Control

Group I: Enhanced Usual Care plus Financial Incentives plus Mobile Health ApplicationActive Control3 Interventions

Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.

Group II: Enhanced Usual Care plus Financial IncentivesActive Control2 Interventions

Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.

Group III: Basic Usual CareActive Control1 Intervention

Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.

Group IV: Enhanced Usual CareActive Control1 Intervention

Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.

0 / 3Eligibility criteria met